Literature DB >> 28425681

Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) into Schedule I. Temporary Scheduling Order.

.   

Abstract

The Administrator of the Drug Enforcement Administration is issuing this temporary scheduling order to schedule six synthetic cannabinoids: methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA]; methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate [5F-AMB]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide [5F-APINACA, 5F-AKB48]; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide [ADB-FUBINACA]; methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate [MDMB-CHMICA, MMB-CHMINACA] and methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [MDMB-FUBINACA], and their optical, positional, and geometric isomers, salts, and salts of isomers into schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act. This action is based on a finding by the Administrator that the placement of these synthetic cannabinoids into schedule I of the Controlled Substances Act is necessary to avoid an imminent hazard to the public safety. As a result of this order, the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances will be imposed on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle, 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA or MDMB-FUBINACA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28425681

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  6 in total

1.  Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Neurotoxicology       Date:  2018-11-12       Impact factor: 4.294

2.  Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073.

Authors:  Ziva D Cooper; Justin L Poklis; Fei Liu
Journal:  Neuropharmacology       Date:  2017-11-14       Impact factor: 5.250

3.  Determining the subjective effects of TFMPP in human males.

Authors:  Reem K Jan; Joanne C Lin; Heeseung Lee; Janie L Sheridan; Rob R Kydd; Ian J Kirk; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2010-06-16       Impact factor: 4.530

Review 4.  When good times go bad: managing 'legal high' complications in the emergency department.

Authors:  Charles R Caffrey; Patrick M Lank
Journal:  Open Access Emerg Med       Date:  2017-12-20

Review 5.  Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications.

Authors:  Carolina Lobato-Freitas; Andreia Machado Brito-da-Costa; Ricardo Jorge Dinis-Oliveira; Helena Carmo; Félix Carvalho; João Pedro Silva; Diana Dias-da-Silva
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

6.  Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity.

Authors:  Marilisa P Dimmito; Azzurra Stefanucci; Stefano Pieretti; Paola Minosi; Szabolcs Dvorácskó; Csaba Tömböly; Gokhan Zengin; Adriano Mollica
Journal:  Biomolecules       Date:  2019-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.